MEDP Medpace Holdings, Inc. Insider Trading

MEDP General Counsel sold 16,349 shares at $450.00 on 2026-05-28, reducing holdings 44.6% to 20,343 shares; stock now -28.2% from 52-week high.

Stephen P Ewald, General Counsel & Corp. Secy., sold 16,349 shares (16.3K shares) of Medpace Holdings at $450.00, generating $7,357,050.00 ($7.4M) and reducing his non-derivative holdings by 44.6% from 36,692 shares to 20,343 shares. The stock has declined 28.2% from its 52-week high of $628.92 and is currently trading at $451.47, near the transaction price. Ewald's cross-ticker history shows 5 prior sells against only 1 buy across all holdings. The company itself remains fundamentally solid with $706.6M in quarterly revenue, $123.9M net income, and 20.0% annual revenue growth, trading at a P/E of 28.01 with a $12.9B market cap, suggesting the sale reflects a portfolio decision rather than distress. Investors should note the substantial share reduction by a senior officer concurrent with a significant retreat from the stock's recent highs.

MEDP President Geiger sells 31,707 shares for $14.4M; reduces stake by -67.9% to 15,000 shares post-transaction.

Jesse J. Geiger, President of Medpace Holdings, sold 31,707 shares at $455.30 on 2026-03-17 for $14,436,197.10, reducing his holdings from 46,707 shares to 15,000 shares—a substantial -67.9% reduction. The transaction occurred while MEDP trades at $460.92, within the 52-week range of $277.23–$620.59 but notably -25.7% from the 52-week high; over 90 days the stock declined -18.9%. Within his ticker-specific history at MEDP, Geiger has 5 prior trades with mixed timing outcomes: 3 of 5 prior sells achieved negative 90-day returns (well-timed), while his cross-ticker track record across 6 prior sells shows an average 90-day return of +1.8% and a 66.67% well-timed rate. The company shows solid fundamentals with $659.9M in latest quarterly revenue, net income of $111.1M, annual revenue growth of +20.0%, and a P/E of 27.27. The magnitude of this sale—disposing of nearly two-thirds of his prior stake—represents a meaningful shift in his personal equity exposure to the company where he serves as President.

CEO Troendle sells 28,876 shares ($17.1M) across two days at $592.70 blended average, near 52-week high.

August J. Troendle, CEO of Medpace Holdings, executed 2 separate sales totaling 28,876 shares for $17,114,846.56 on 2025-12-01 and 2025-12-02 at blended average price $592.70, reducing his holdings from 675,728 to 646,852 shares (-4.3%). The transaction occurred near the 52-week high of $618.49, with current price at $576.49 showing a -6.8% drawdown. Notably, Troendle has executed 5 consecutive sales at this ticker within a 7-day window (2025-11-21 through 2025-12-02), representing sustained sequential liquidation. While his cross-ticker track record shows 62.50% well-timed sell rate at 90 days with +8.4% average 90-day return, those gains suggest his prior sells were historically early exits before rallies—a pattern that currently conflicts with the stock's -3.0% 30-day decline since these recent transactions.

MEDP CEO Troendle sells 56,482 shares for $34,074,469.74 in 2 transactions, 11/26–11/28

CEO August J. Troendle executed 2 separate sales totaling 56,482 shares for $34,074,469.74 on November 26 and 28, 2025, reducing his holdings by 7.7% to 675,728 shares. The blended average sale price of $603.28 sits 2.6% above the current price of $587.98 and near the 52-week high of $618.49, positioning this as a high-priced exit. At Medpace, Troendle has executed 5 straight sells over 6 days (November 20–December 1), marking a sustained pattern of share reduction at elevated valuations. His cross-ticker track record shows a 66.67% well-timed rate on 20 prior sells with positive average returns, but this does not predict accuracy at this specific ticker: the company trades at a rich P/E of 38.26 despite solid 11.8% annual revenue growth and healthy net income of $111,135,000.00. The sustained concentrated selling in recent days warrants tracking whether this reflects conviction to exit at peak prices or liquidity-driven activity.

MEDP CEO Troendle sells 101,417 shares for $61,967,338.34 over two days near 52-week high

CEO August J. Troendle executed two separate sales totaling 101,417 shares for $61,967,338.34 on November 24–25, 2025, at prices of $607.78 and $615.52, reducing his holdings from 833,627 to 732,210 shares (a -12.2% reduction). The sales occurred within 1.9% of the 52-week high of $618.49, reflecting execution near peak valuation. His cross-ticker track record shows 20 prior sells with an 88.89% well-timed rate and an average 90-day return of -0.2%, indicating a pattern of selling before downturns; however, his five prior MEDP sales all occurred within the preceding week (November 18–26) with no measurable 90-day outcomes yet. Medpace's fundamentals remain solid with $659.9M quarterly revenue, +11.8% annual growth, and 39.47 P/E, though the cumulative effect of repeated insider selling concentrated near the 52-week high merits monitoring for any signal of executive reassessment of near-term valuation.

EVP Susan Burwig sells 20,000 MEDP shares for $12.2M; reduces stake 42.1%, holds 27,500 post-sale

Susan Burwig, Executive Vice President of Operations, sold 20,000 shares of Medpace Holdings for $12,183,000.00 on 2025-11-24, reducing her position by 42.1% to 27,500 shares remaining. The sale occurred at $609.15, near the 52-week high of $618.49, suggesting opportunistic execution into strength. At Medpace specifically, Burwig has executed 5 prior trades with mixed outcomes: her most recent measurable result (2025-07-28) showed a +34.4% 90-day return after selling, but a 2024-06-05 sale produced a -12.8% 90-day return, indicating her timing at this ticker has been inconsistent. The broader stock has rallied +28.3% over 90 days and +1.7% over 30 days, and fundamentals remain solid with +11.8% annual revenue growth and net income of $111,135,000.00 on $659,903,000.00 quarterly revenue, though valuation has compressed at a P/E of 39.47.

CFO Brady Kevin M. sold 3,000 shares of MEDP at $590.35 for $1,771,050; holds 5,830 shares post-sale (-34.0%).

Brady Kevin M. (CFO & Treasurer) executed a substantial open-market sale of 3,000 shares at $590.35 on 2025-11-21, reducing his holdings by 34.0% from 8,830 to 5,830 shares. The sale occurred near the 52-week high of $618.49 (-1.1% from peak), and MEDP stock has since appreciated 1.1% in the 30-day window post-transaction. His cross-ticker track record shows 2 prior open-market sales with a 90-day well-timed rate of 50.00%, while his MEDP-specific history (2 prior trades) included one well-timed 90-day outcome. The company's fundamentals remain solid with annual revenue growth of +11.8%, net income of $111,135,000, and a P/E of 39.81. The sale's proximity to a 52-week high and the substantial reduction in insider ownership stake warrant scrutiny of motivations and any near-term forward guidance shifts.

CEO Troendle sells 28,688 shares for $17,031,557.14 (blended avg $593.68) across 2 sales on Nov 20–21; stock now at $618.49 (+0.0% from 52-week high).

Medpace CEO August J. Troendle executed 2 separate sales totaling 28,688 shares for $17,031,557.14 at blended average price $593.68 on November 20–21, 2025, reducing his stake from 862,315 shares to 833,627 shares (-3.3%). The sales occurred near the stock's 52-week high of $618.49, with the current price at +0.0% from that peak and +31.8% over 90 days. Across his cross-ticker open-market history, Troendle's prior 20 sells averaged a poorly-timed 90-day return of +2.2% (showing the stock typically rose after his sales), though his 90-day well-timed rate stands at 90.91%, indicating his recent sales have largely preceded declines. At Medpace specifically, five prior sales in quick succession (Nov 14–24) lack measurable outcomes as they are too recent. The company's fundamentals remain robust with annual revenue growth of +11.8%, net income of $111,135,000.00, and a market cap of $17,421,764,243.27, though the P/E of 40.24 reflects a premium valuation. The confluence of substantial share liquidation near all-time highs by the CEO, combined with his strong recent timing track record across other holdings, merits investor attention to near-term price action.

CEO Troendle sold 31,053 shares in 2 transactions (Nov 18-19) for $18,376,704.78 at $591.79 avg, retaining 862,315 shares

CEO August J. Troendle executed 2 separate sales totaling 31,053 shares for $18,376,704.78 between November 18–19, 2025, at a blended average price of $591.79, reducing his holdings by 3.5% to 862,315 shares. The timing is notable: these transactions occurred as the stock rallied +7.4% over 30 days and +26.4% over 90 days, approaching its 52-week high of $605.20 (current price $586.16 is -3.2% from that peak). Across his cross-ticker track record, Troendle has demonstrated a 92.31% well-timed sell rate over the long term, suggesting experienced execution; however, his 5 most recent MEDP trades (all within days of this filing) have outcomes not yet measurable at 30 or 90 days. The strong recent price momentum and elevated valuation (P/E 38.14) provide context for the sale, though fundamentals remain solid with annual revenue growth of +11.8%.

Director Kraft sells 6.5K MEDP shares ($3.8M) at $591.85; reduces stake 88.6%, retains only 833 shares post-transaction

Director Robert O. Kraft executed a substantial open-market sale, liquidating 6,472 shares of Medpace Holdings at $591.85 on 2025-11-14, reducing his holdings from 7,305 shares to 833 shares—an 88.6% reduction in position size. The sale occurs near the 52-week high ($605.20, currently -2.5% below peak), following a strong 11.8% rally over the prior 30 days and 26.7% over 90 days. At this same ticker (MEDP), Kraft's prior two 2024 sales realized -6.4% and -6.4% at the 30-day mark with -12.5% and -16.5% 90-day returns respectively, demonstrating pattern of selling ahead of subsequent declines; 2 of his 3 prior MEDP sales were well-timed at the 90-day mark. His cross-ticker track record shows a 66.67% well-timed rate on prior sells, though his most recent same-ticker transactions align with a history of sales executed before pullbacks. The magnitude of this liquidation—retaining only 833 shares—and its execution near recent highs warrant attention to whether the timing again precedes a reversal.